Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B J Foster

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1988
Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleateB J Foster, K R Grotzinger, W M McKoy, et al.
British Journal of Cancer|February 1, 1993
Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusionB J Foster, D R Newell, L A Gumbrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activityB J Foster, R A Wiegand, S Pugh, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 12, 2014
Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipientsB J Foster, M Dahhou, X Zhang, et al.
Cancer Research|February 1, 1992
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation schemeM A Graham, D R Newell, B J Foster, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIPB J Foster, B J Harding, M K Wolpert-DeFilippes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1995
Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934)P LoRusso, B J Foster, E Poplin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalationB J Foster, D R Newell, M A Graham, et al.
British Journal of Cancer|February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277B J Foster, D R Newell, J Carmichael, et al.
Investigational New Drugs|January 1, 1985
Echinomycin: the first bifunctional intercalating agent in clinical trialsB J Foster, K Clagett-Carr, D D Shoemaker, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|January 1, 1988
Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleateB J Foster, K R Grotzinger, W M McKoy, et al.
British Journal of Cancer|February 1, 1993
Phase I trial with pharmacokinetics of CB10-277 given by 24 hours continuous infusionB J Foster, D R Newell, L A Gumbrell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activityB J Foster, R A Wiegand, S Pugh, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 12, 2014
Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipientsB J Foster, M Dahhou, X Zhang, et al.
Cancer Research|February 1, 1992
Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation schemeM A Graham, D R Newell, B J Foster, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIPB J Foster, B J Harding, M K Wolpert-DeFilippes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1995
Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934)P LoRusso, B J Foster, E Poplin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalationB J Foster, D R Newell, M A Graham, et al.
British Journal of Cancer|February 1, 1993
Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277B J Foster, D R Newell, J Carmichael, et al.
Investigational New Drugs|January 1, 1985
Echinomycin: the first bifunctional intercalating agent in clinical trialsB J Foster, K Clagett-Carr, D D Shoemaker, et al.
Pageof 4